



30 January 2023

Tender results

Pharmac has resolved to award tenders for Principal Supply Status for some products included in the 2021/22 Invitation to Tender, dated 1 November 2021 and the 2022/23 Invitation to Tender, dated 31 October 2022.

Some of the Pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of Pharmaceuticals that are subject to such contracts should continue to supply their Pharmaceuticals under those contracts. Pharmac will continue to subsidise those Pharmaceuticals accordingly until such time as those Pharmaceuticals are delisted.

Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:

- **For new listings**, by 4pm on the 12th of February 2023 or the 5th of the month prior to listing, whichever is earlier
- **For price changes**, by 4pm on the 12th of the month prior to the date of subsidy change

Pharmac cannot list a product (and Pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website – <https://www.Pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/Pharmaceutical-product-specifications-the-change-process>

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (<http://www.pgnz.org.nz/about-us-1/Pharmacode>) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (<http://www.nzulm.org.nz/sponsors>). Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and Pharmacies cannot claim) without the correct Pharmacode.

2021/22 Tender – Principal Supply Status applies until 30 June 2025

Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule

1. *Tenders awarded to currently listed Pharmaceuticals where at least one other brand is listed*

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of listing	Principal Supply Status date	Brand (Supplier) affected by delisting
Hydrocortisone	Crm 1%; 500 g tub	\$17.15	\$20.40	Noumed (Noumed)	1 March 2023	1 August 2023	PSM (API Consumer Brands)
Pethidine hydrochloride	Tab 50 mg; 10 tablet bottle pack	\$4.70	\$8.68	Noumed Pethidine (Noumed)	1 March 2023	1 August 2023	PSM (API Consumer Brands)

Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.

The decisions were as follows:

2. *Tenders awarded to currently listed Pharmaceuticals where at least one other brand is listed.*

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV limit	Listing date	Principal Supply date	Brand (Supplier) affected by delisting
Hydrocortisone	Crm 1%; 500 g tub	\$17.15	\$20.40	Noumed (Noumed)	5%	1 March 2023	1 August 2023	PSM (API Consumer Brands)
Pethidine hydrochloride	Tab 50 mg; 10 tablet bottle pack	\$4.70	\$8.68	Noumed Pethidine (Noumed)	5%	1 March 2023	1 August 2023	PSM (API Consumer Brands)

2022/23 Tender – Principal Supply Status applies until 30 June 2026

Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule

3. Tenders awarded to currently listed Pharmaceuticals where no other brand is listed

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of subsidy change	Principal Supply date
Cetirizine hydrochloride	Tab 10 mg; 100 tablet blister pack	\$7.50	\$1.71	Zista (Teva)	1 April 2023	1 September 2023
Flecainide acetate	Cap long-acting 100 mg; 90 capsule blister pack	\$108.65	\$35.78	Flecainide Controlled Release Teva (Teva)	1 March 2023	1 August 2023
Flecainide acetate	Cap long-acting 200 mg; 90 capsule blister pack	\$167.92	\$54.28	Flecainide Controlled Release Teva (Teva)	1 March 2023	1 August 2023
Roxithromycin	Tab 150 mg; 50 tablet blister pack	\$29.50	\$13.19	Arrow-Roxithromycin (Teva)	1 March 2023	1 August 2023
Roxithromycin	Tab 300 mg; 50 tablet blister pack	\$35.50	\$25.00	Arrow-Roxithromycin (Teva)	1 March 2023	1 August 2023

Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.

4. Tenders awarded to Pharmaceuticals where no other brand is listed

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV limit	Date of price change	Principal Supply date
Cetirizine hydrochloride	Tab 10 mg; 100 tablet blister pack	\$7.50	\$1.71	Zista (Teva)	5%	1 April 2023	1 September 2023
Flecainide acetate	Cap long-acting 100 mg; 90 capsule blister pack	\$108.65	\$35.78	Flecainide Controlled Release Teva (Teva)	5%	1 March 2023	1 August 2023
Flecainide acetate	Cap long-acting 200 mg; 90 capsule blister pack	\$167.92	\$54.28	Flecainide Controlled Release Teva (Teva)	5%	1 March 2023	1 August 2023
Roxithromycin	Tab 150 mg; 50 tablet blister pack	\$29.50	\$13.19	Arrow-Roxithromycin (Teva)	5%	1 March 2023	1 August 2023
Roxithromycin	Tab 300 mg; 50 tablet blister pack	\$35.50	\$25.00	Arrow-Roxithromycin (Teva)	5%	1 March 2023	1 August 2023

For products included in the 2020/21, 2021/22 and 2022/23 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.

If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.